

Electronic supplementary information for the manuscript

“Highly selective reactions of C₆₀Cl₆ with thiols for synthesis of functionalized [60]fullerene derivatives”

*Ekaterina A. Khakina,^a Anastasiya A. Yurkova,^a Alexander S. Peregudov,^b Sergey I. Troyanov,^c
Vyacheslav V. Trush,^d Andrey I. Vovk,^d Alexander V. Mumyatov,^a Vyacheslav M. Martynenko,^a
Jan Balzarini^e and Pavel A. Troshin^{*}*

Table of contents:

	<i>page</i>
Selected spectroscopic data	3-5
X-ray crystallography for 1c	6
Fig. S1. ESI MS spectrum of compound 1a	8
Fig. S2. ¹ H NMR spectrum of compound 1a	8
Fig. S3. High-field part of the ¹³ C NMR spectrum of compound 1a	9
Fig. S4. Low-field part of the ¹³ C NMR spectrum of compound 1a	9
Fig. S5. ESI mass spectrum of compound 1b	10
Fig. S6. ¹ H NMR spectrum of compound 1b	10
Fig. S7. High-field part of the ¹³ C NMR spectrum of compound 1b	11
Fig. S8. Low-field part of the ¹³ C NMR spectrum of compound 1b	11
Fig. S9. ESI mass spectrum of compound 1c	12
Fig. S10. ¹ H NMR spectrum of compound 1c	12
Fig. S11. High-field part of the ¹³ C NMR spectrum of compound 1c	13
Fig. S12. Low-field part of the ¹³ C NMR spectrum of compound 1c	13
Fig. S13. ESI mass spectrum of compound 1d	14
Fig. S14. ¹ H NMR spectrum of compound 1d	14
Fig. S15. High-field part of the ¹³ C NMR spectrum of compound 1d	15
Fig. S16. Low-field part of the ¹³ C NMR spectrum of compound 1d	15
Fig. S17. H-H COSY NMR spectrum of compound 1d	16
Fig. S18. H-C HMQC NMR spectrum of compound 1d	17
Fig. S19. H-C HMBC NMR spectrum of compound 1d	18
Fig. S20. HPLC profile of compound 1e (Phenomenex Luna 5u C18(2) column, 150 x 4.6 mm, acetonitrile/toluene 70/30 v/v, flow rate 1 mL min ⁻¹)	19
Fig. S21. ESI mass spectrum of compound 1e	19

Fig. S22. ^1H NMR spectrum of compound 1e	20
Fig. S23. High-field part of the ^{13}C NMR spectrum of compound 1e	20
Fig. S24. Low-field part of the ^{13}C NMR spectrum of compound 1e	21
Fig. S25. ESI mass spectrum of compound 1f	21
Fig. S26. ^1H NMR spectrum of compound 1f	22
Fig. S27. High-field part of the ^{13}C NMR spectrum of compound 1f	22
Fig. S28. Low-field part of the ^{13}C NMR spectrum of compound 1f	23
Fig. S29. ESI mass spectrum of compound 1g	23
Fig. S30. ^1H NMR spectrum of compound 1g	24
Fig. S31. High-field part of the ^{13}C NMR spectrum of compound 1g	24
Fig. S32. Low-field part of the ^{13}C NMR spectrum of compound 1g	25
Fig. S33. ESI mass spectrum of compound 1h	25
Fig. S34. ^1H NMR spectrum of compound 1h	26
Fig. S35. High-field part of the ^{13}C NMR spectrum of compound 1h	26
Fig. S36. Low-field part of the ^{13}C NMR spectrum of compound 1h	27
Fig. S37. ESI mass spectrum of compound 1i	27
Fig. S38. ^1H NMR spectrum of compound 1i	28
Fig. S39. High-field part of the ^{13}C NMR spectrum of compound 1i	28
Fig. S40. Low-field part of the ^{13}C NMR spectrum of compound 1i	29
Fig. S41. ESI mass spectrum of compound 2e (peak with $m/z=984$ corresponds to the $[\text{M}+\text{CN}]^-$ anion)	29
Fig. S42. ^1H NMR spectrum of compound 2e	30
Fig. S43. High-field part of the ^{13}C NMR spectrum of compound 2e	30
Fig. S44. Low-field part of the ^{13}C NMR spectrum of compound 2e	31
Fig. S45 Relative IC_{50} values characterizing inhibitory activities of 1i-K (1) and 1h-K (2) with respect to protein tyrosine phosphatases PTP1B (green), TC-PTP (yellow), PTP β (red) and LAR-PTP (blue)	31

Selected spectroscopic data:

1a. ^1H NMR (600 MHz, CDCl_3 , δ , ppm): 0.90 (t, 15H), 1.28 (br. s, 80H), 1.47-1.52 (m, 10H), 1.77-1.82 (m, 10H), 3.23-3.29 (m, 8H), 3.35 (t, 2H), 5.12 (s, 1H).

^{13}C NMR (150 MHz, CDCl_3 , δ , ppm): 14.17 ($\underline{\text{C}}\text{H}_3$), 22.73 ($\underline{\text{C}}\text{H}_2$), 28.56 ($\underline{\text{C}}\text{H}_2$), 29.20 ($\underline{\text{C}}\text{H}_2$), 29.24 ($\underline{\text{C}}\text{H}_2$), 29.28 ($\underline{\text{C}}\text{H}_2$), 29.38 ($\underline{\text{C}}\text{H}_2$), 29.42 ($\underline{\text{C}}\text{H}_2$), 29.48 ($\underline{\text{C}}\text{H}_2$), 29.54 ($\underline{\text{C}}\text{H}_2$), 29.63 ($\underline{\text{C}}\text{H}_2$), 29.65 ($\underline{\text{C}}\text{H}_2$), 29.71 ($\underline{\text{C}}\text{H}_2$), 29.76 ($\underline{\text{C}}\text{H}_2$), 31.96 ($\underline{\text{C}}\text{H}_2$), 33.44 ($\underline{\text{C}}\text{H}_2$), 33.68 ($\underline{\text{C}}\text{H}_2$), 34.31 ($\underline{\text{C}}\text{H}_2$), 39.23 ($\underline{\text{C}}\text{H}_2$), 53.89 (sp^3 fullerene cage), 55.82 (sp^3 fullerene cage), 56.49 (sp^3 fullerene cage), 60.38 (sp^3 fullerene cage), 143.10, 143.16, 143.22, 143.27, 143.38, 143.90, 144.04, 144.10, 144.23, 144.36, 144.61, 145.08, 145.17, 146.51, 146.75, 146.80, 147.55, 147.90, 148.07, 148.09, 148.25, 148.46, 148.59, 148.71, 150.15, 151.02, 152.97, 154.17.

ESI MS: $m/z=1727$ ($[\text{M}-\text{H}]^-$).

1b. ^1H NMR (600 MHz, CDCl_3 , δ , ppm): 3.73 (s, 6H), 3.79 (s, 9H), 4.06-4.11 (m, 4H), 4.12-4.20 (m, 4H), 4.26 (s, 2H), 5.56 (s, 1H).

^{13}C NMR (150 MHz, CDCl_3 , δ , ppm): 35.12 ($\underline{\text{C}}\text{H}_3$), 35.38 ($\underline{\text{C}}\text{H}_3$), 36.30 ($\underline{\text{C}}\text{H}_3$), 52.71 ($\underline{\text{C}}\text{H}_2$), 52.78 ($\underline{\text{C}}\text{H}_2$), 52.86 ($\underline{\text{C}}\text{H}_2$), 53.69 (sp^3 fullerene cage), 55.74 (sp^3 fullerene cage), 56.78 (sp^3 fullerene cage), 60.02 (sp^3 fullerene cage), 142.20, 142.73, 142.88, 143.38, 143.50, 143.87, 143.96, 144.12, 144.23, 144.32, 144.37, 144.53, 144.73, 146.54, 146.75, 146.80, 147.54, 148.00, 148.12, 148.23, 148.32, 148.47, 148.78, 148.88, 149.26, 150.01, 153.02, 153.32, 169.80 ($\underline{\text{C}}\text{OOCH}_3$), 169.98 ($\underline{\text{C}}\text{OOCH}_3$), 170.27 ($\underline{\text{C}}\text{OOCH}_3$).

ESI MS: $m/z=1245$ ($[\text{M}-\text{H}]^-$).

1c. ^1H NMR (600 MHz, CDCl_3 , δ , ppm): 1.22-1.25 (m, 6H), 1.26-1.34 (m, 9H), 3.92-4.04 (m, 2H), 4.06 (s, 2H), 4.09-4.12 (m, 2H), 4.15-4.19 (m, 6H), 4.20-4.40 (m, 8H).

^{13}C NMR (150 MHz, CDCl_3 , δ , ppm): 14.12 ($\underline{\text{C}}\text{H}_3$), 14.17 ($\underline{\text{C}}\text{H}_3$), 14.21 ($\underline{\text{C}}\text{H}_3$), 35.34 ($\underline{\text{C}}\text{H}_2$), 35.61 ($\underline{\text{C}}\text{H}_2$), 36.44 ($\underline{\text{C}}\text{H}_2$), 53.73 (sp^3 fullerene cage), 55.78 (sp^3 fullerene cage), 56.79 (sp^3 fullerene cage), 60.08 (sp^3 fullerene cage), 61.82 ($\underline{\text{O}}\underline{\text{C}}\text{H}_2$), 61.89 ($\underline{\text{O}}\underline{\text{C}}\text{H}_2$), 61.95 ($\underline{\text{O}}\underline{\text{C}}\text{H}_2$), 142.31, 142.82, 142.89, 143.37, 143.58, 143.97, 144.07, 144.12, 144.22, 144.30, 144.46, 144.52, 144.80, 146.54, 146.76, 146.81, 147.54, 147.99, 148.12, 148.22, 148.31, 148.46, 148.77, 148.87, 149.39, 150.15, 153.14, 153.37, 169.34 ($\underline{\text{C}}\text{OOCH}_2\text{CH}_3$), 169.53 ($\underline{\text{C}}\text{OOCH}_2\text{CH}_3$), 169.79 ($\underline{\text{C}}\text{OOCH}_2\text{CH}_3$).

ESI MS: $m/z=1315$ ($[\text{M}-\text{H}]^-$).

1d. ^1H NMR (600 MHz, CDCl_3 , δ , ppm): 0.87-0.95 (m, 30H), 1.12-1.23 (m, 5H), 1.36-1.48 (m, 5H), 1.64-1.78 (m, 5H), 3.60 (s, 1H), 3.63 (d, 1H), 3.87-4.20 (m, 16H), 4.26 (s, 2H), 5.55 (s, 1H).

^{13}C NMR (150 MHz, CDCl_3 , δ , ppm): 11.22 ($\underline{\text{C}}\text{H}_3$), 11.27 ($\underline{\text{C}}\text{H}_3$), 16.37 ($\underline{\text{C}}\text{H}_3$), 16.41 ($\underline{\text{C}}\text{H}_3$), 25.94 ($\underline{\text{C}}\text{H}_2\text{CH}_3$), 25.97 ($\underline{\text{C}}\text{H}_2\text{CH}_3$), 34.04 ($\underline{\text{C}}\text{H}$), 34.07 ($\underline{\text{C}}\text{H}$), 34.08 ($\underline{\text{C}}\text{H}$), 35.38 ($\underline{\text{S}}\underline{\text{C}}\text{H}_2$),

35.63 (SCH₂), 36.43 (SCH₂), 53.72 (sp³ fullerene cage), 55.76 (sp³ fullerene cage), 56.85 (sp³ fullerene cage), 60.08 (sp³ fullerene cage), 70.44 (OCH₂), 70.51 (OCH₂), 70.60 (OCH₂), 142.34, 142.80, 142.94, 143.10, 143.35, 143.57, 143.95, 144.09, 144.21, 144.31, 144.44, 144.51, 144.80, 146.53, 146.76, 146.80, 147.51, 147.98, 148.09, 148.20, 148.29, 148.43, 148.75, 148.85, 149.40, 150.15, 153.17, 153.29, 169.46 (COOCH₂CH), 169.61 (COOCH₂CH), 169.96 (COOCH₂CH).

ESI MS: m/z=1526 ([M-H]).

1e. ¹H NMR (600 MHz, CDCl₃, δ, ppm): 2.76 (t, 2H), 2.86 (m, 6H), 2.94 (t, 2H), 3.50 (m, 6H), 3.61 (t, 2H), 3.73 (m, 17H), 5.18 (s, 1H).

¹³C NMR (150 MHz, CDCl₃, δ, ppm): 27.95 (CH₂), 28.19 (CH₂), 33.08 (CH₂), 33.90 (CH₂), 34.41 (CH₂), 34.95 (CH₂), 51.93 (OCH₃), 51.97 (OCH₃), 51.99 (OCH₃), 53.81 (sp³ fullerene cage), 55.80 (sp³ fullerene cage), 56.58 (sp³ fullerene cage), 60.27 (sp³ fullerene cage), 128.24, 129.05, 142.66, 142.90, 143.10, 143.66, 143.98, 144.23, 144.29, 144.36, 144.52, 144.55, 144.80, 146.50, 146.73, 146.79, 147.57, 147.97, 148.12, 148.22, 148.28, 148.48, 148.72, 148.84, 149.68, 150.57, 153.04, 153.70, 171.89 (COOCH₃), 171.91 (COOCH₃), 171.93 (COOCH₃).

ESI MS: m/z=1315 ([M-H]).

1f. ¹H NMR (600 MHz, CDCl₃, δ, ppm): 1.42-1.46 (m, 45H), 3.40-3.57 (m, 20H), 5.18 (s, 1H), 5.33-5.50 (m, 5H).

¹³C NMR (150 MHz, CDCl₃, δ, ppm): 28.47 (CH₃), 28.59 (CH₃), 28.67 (CH₃), 33.45 (CH₂), 33.73 (CH₂), 34.39 (CH₂), 40.07 (CH₂), 40.30 (CH₂), 40.39 (CH₂), 53.58 (sp³ fullerene cage), 55.56 (sp³ fullerene cage), 56.37 (sp³ fullerene cage), 60.39 (sp³ fullerene cage), 79.47 (OC(CH₃)₃), 79.54 (OC(CH₃)₃), 79.61 (OC(CH₃)₃), 142.67, 142.89, 143.11, 143.38, 143.65, 143.99, 144.20, 144.27, 144.36, 144.47, 144.50, 144.80, 146.49, 146.73, 146.77, 147.54, 147.94, 148.09, 148.20, 148.28, 148.46, 148.71, 148.83, 149.74, 150.53, 153.14, 153.73, 155.68 (COOOC(CH₃)₃), 155.79 (COOOC(CH₃)₃), 155.85 (COOOC(CH₃)₃).

ESI MS: m/z=1601 ([M-H]).

1g. ¹H NMR (600 MHz, (CD₃)₂CO:CS₂ (1:1), δ, ppm): 4.06-4.19 (m, 6H), 4.24-4.29 (m, 2H), 4.35 (s, 2H).

¹³C NMR (150 MHz, (CD₃)₂CO:CS₂ (1:1), δ, ppm): 35.16 (CH₂), 35.47 (CH₂), 36.41 (CH₂), 53.63 (sp³ fullerene cage), 55.78 (sp³ fullerene cage), 56.71 (sp³ fullerene cage), 142.96, 143.13, 143.20, 143.34, 143.81, 144.09, 144.17, 144.21, 144.25, 144.49, 144.69, 145.12, 146.59, 146.80, 146.87, 147.02, 147.57, 148.00, 148.12, 148.32, 148.47, 148.67, 148.77, 150.03, 150.64, 153.54, 153.70, 169.60 (COOH), 169.88 (COOH), 170.01 (COOH).

ESI MS: m/z=1175 ([M-H]); 1083 ([M-RSH]).

1h. ¹H NMR (600 MHz, (CD₃)₂CO:CS₂ (1:1), δ, ppm): 2.69 (t, 1H), 2.78-2.86 (m, 8H), 2.92 (t, 1H), 3.46-3.55 (m, 7H), 3.59 (t, 1H), 3.65 (t, 2H), 5.43 (s, 1H).

^{13}C NMR (150 MHz, $(\text{CD}_3)_2\text{CO}:\text{CS}_2$ (1:1), δ , ppm): 33.49 ($\underline{\text{CH}_2}$), 33.53 ($\underline{\text{CH}_2}$), 34.04 ($\underline{\text{CH}_2}$), 34.48 ($\underline{\text{CH}_2}$), 34.57 ($\underline{\text{CH}_2}$), 53.98 (sp^3 fullerene cage), 55.98 (sp^3 fullerene cage), 56.82 (sp^3 fullerene cage), 60.35 (sp^3 fullerene cage), 143.16, 143.21, 143.37, 143.90, 144.21, 144.23, 144.27, 144.50, 144.63, 145.16, 145.19, 146.57, 146.79, 146.86, 147.64, 148.01, 148.15, 148.17, 148.34, 148.53, 148.65, 148.77, 150.35, 151.12, 153.55, 154.20, 171.91 ($\underline{\text{COOH}}$), 171.99 ($\underline{\text{COOH}}$), 172.02 ($\underline{\text{COOH}}$).

ESI MS: $m/z=1245$ ($[\text{M}-\text{H}]^-$); 1140 ($[\text{M}-\text{RSH}]^-$); 622 ($[\text{M}-2\text{H}]^{2-}$), 613.5 ($[\text{M}-\text{H}_2\text{O}-\text{H}]^{2-}$).

1i. ^1H NMR (600 MHz, $(\text{CD}_3)_2\text{CO}:\text{CS}_2$ (1:1), δ , ppm): 1.26-1.36 (m, 50H), 1.54-1.60 (m, 20H), 1.80-1.87 (m, 10H), 2.25-2.27 (m, 10H), 3.23-3.34 (m, 10H), 5.15 (s, 1H).

^{13}C NMR (150 MHz, $(\text{CD}_3)_2\text{CO}:\text{CS}_2$ (1:1), δ , ppm): 25.19 ($\underline{\text{CH}_2}$), 25.22 ($\underline{\text{CH}_2}$), 29.52 ($\underline{\text{CH}_2}$), 29.63 ($\underline{\text{CH}_2}$), 29.80 ($\underline{\text{CH}_2}$), 30.00 ($\underline{\text{CH}_2}$), 30.05 ($\underline{\text{CH}_2}$), 30.09 ($\underline{\text{CH}_2}$), 33.6 ($\underline{\text{CH}_2}$), 33.71 ($\underline{\text{CH}_2}$), 33.87 ($\underline{\text{CH}_2}$), 53.99 (sp^3 fullerene cage), 55.91 (sp^3 fullerene cage), 56.59 (sp^3 fullerene cage), 60.50 (sp^3 fullerene cage), 143.19, 143.22, 143.28, 143.60, 144.01, 144.12, 144.17, 144.34, 144.39, 144.43, 144.69, 145.24, 145.34, 146.77, 146.85, 147.60, 147.95, 148.12, 148.30, 148.51, 148.59, 148.71, 150.35, 151.22, 153.15, 154.34, 174.20 ($\underline{\text{COOH}}$), 174.26 ($\underline{\text{COOH}}$).

ESI MS: $m/z=1807$ ($[\text{M}-\text{H}]^-$).


2e. ^1H NMR (600 MHz, CDCl_3 , δ , ppm): 3.05-3.11 (m, 4H), 3.82 (s, 6H), 3.84-3.92 (m, 4H).

^{13}C NMR (150 MHz, $(\text{CD}_3)_2\text{CO}:\text{CS}_2$ (1:1), δ , ppm): 28.06 ($\underline{\text{CH}_2}$), 35.38 ($\underline{\text{CH}_2}$), 51.58 ($\underline{\text{OCH}_3}$), 57.21 (sp^3 fullerene cage), 128.44, 137.80, 138.87, 141.21, 141.78, 142.06, 142.52, 142.74, 142.82, 143.29, 143.49, 143.51, 143.55, 143.97, 144.14, 144.41, 144.44, 144.49, 144.51, 144.61, 144.69, 145.36, 145.79, 145.96, 147.07, 147.17, 147.35, 147.69, 148.83, 150.06, 154.06, 170.58 ($\underline{\text{COOCH}_3}$).

ESI MS: $m/z=984$ ($[\text{M}+\text{CN}]^+$).

X-ray crystallography for **1c**

Data collection for single crystal of **1c** ($0.52 \times 0.33 \times 0.16 \text{ mm}^3$) was carried out with an IPDS diffractometer (Stoe) at 100 K ($\lambda = 0.71073 \text{ \AA}$). The structure was solved using direct methods (SHELXS97) and anisotropically refined against $|F^2|$ with SHELXL97. Absorption correction was not applied. Crystal data for **1c**: $\text{C}_{80}\text{H}_{36}\text{O}_{10}\text{S}_5$, $M = 1317.39$, triclinic, $P \bar{1}$, $a = 10.3484(3)$, $b = 12.9522(3)$, $c = 20.1312(5) \text{ \AA}$, $\alpha = 90.823(2)$, $\beta = 92.058(2)$, $\gamma = 91.539(2)^\circ$, $V = 2695.25(12) \text{ \AA}^3$, $Z = 2$, $D_{\text{calc}} = 1.623 \text{ g cm}^{-3}$. Anisotropic refinement with 14465 reflections and 911 parameters yielded a conventional $R_1 = 0.053$ for 12359 reflections with $I > 2\sigma(I)$ and $wR_2 = 0.141$ for all reflections. All methylene and methyl hydrogen atoms were placed into geometrically calculated positions and refined in the riding mode. The hydrogen atom attached to the fullerene cage was found in a difference Fourier map and refined isotropically. One sulfide group and one OEt group are orientationally disordered between two positions. For more details see CCDC – 875844.



Scheme 1. Tentative mechanism of the reaction of C_{60}Cl_6 with thiols.




Fig. S1. ESI MS spectrum of compound **1a**




Fig. S2. ^1H NMR spectrum of compound **1a**




Fig. S3. High-field part of the ¹³C NMR spectrum of compound **1a**




Fig. S4. Low-field part of the ¹³C NMR spectrum of compound **1a**




Fig. S5. ESI mass spectrum of compound **1b**




Fig. S6. ¹H NMR spectrum of compound **1b**




Fig. S7. High-field part of the ¹³C NMR spectrum of compound **1b**




Fig. S8. Low-field part of the ¹³C NMR spectrum of compound **1b**




Fig. S9. ESI mass spectrum of compound **1c**




Fig. S10. ¹H NMR spectrum of compound **1c**




Fig. S11. High-field part of the ¹³C NMR spectrum of compound **1c**




Fig. S12. Low-field part of the ¹³C NMR spectrum of compound **1c**




Fig. S13. ESI mass spectrum of compound **1d**




Fig. S14. ¹H NMR spectrum of compound **1d**

ya46f_013001r




Fig. S15. High-field part of the ¹³C NMR spectrum of compound **1d**

ya46f_013001r




Fig. S16. Low-field part of the ¹³C NMR spectrum of compound **1d**




Fig. S17. H-H COSY NMR spectrum of compound **1d**




Fig. S18. H-C HMQC NMR spectrum of compound **1d**




Fig. S19. H-C HMBC NMR spectrum of compound **1d**




Fig. S20. HPLC profile of compound **1e** (Phenomenex Luna 5u C18(2) column, 150 x 4.6 mm, acetonitrile/toluene 70/30 v/v, flow rate 1 mL min⁻¹).




Fig. S21. ESI mass spectrum of compound **1e**




Fig. S22. ¹H NMR spectrum of compound **1e**




Fig. S23. High-field part of the ¹³C NMR spectrum of compound **1e**




Fig. S24. Low-field part of the ^{13}C NMR spectrum of compound **1e**




Fig. S25. ESI mass spectrum of compound **1f**

ya21_2D_001001r




Fig. S26. ¹H NMR spectrum of compound **1f**

ya21_2D_013001r




Fig. S27. High-field part of the ¹³C NMR spectrum of compound **1f**




Fig. S28. Low-field part of the ^{13}C NMR spectrum of compound **1f**




Fig. S29. ESI mass spectrum of compound **1g**




Fig. S30. ¹H NMR spectrum of compound **1g**




Fig. S31. High-field part of the ¹³C NMR spectrum of compound **1g**




Fig. S32. Low-field part of the ¹³C NMR spectrum of compound **1g**




Fig. S33. ESI mass spectrum of compound **1h**




Fig. S34. ¹H NMR spectrum of compound **1h**




Fig. S35. High-field part of the ¹³C NMR spectrum of compound **1h**

ya16_013001r




Fig. S36. Low-field part of the ¹³C NMR spectrum of compound **1h**




Fig. S37. ESI mass spectrum of compound **1i**




Fig. S38. ¹H NMR spectrum of compound **1i**




Fig. S39. High-field part of the ¹³C NMR spectrum of compound **1i**




Fig. S40. Low-field part of the ^{13}C NMR spectrum of compound **1i**




Fig. S41. ESI mass spectrum of compound **2e** (peak with $m/z=984$ corresponds to the $[\text{M}+\text{CN}]^-$ anion)




Fig. S42. ¹H NMR spectrum of compound **2e**




Fig. S43. High-field part of the ¹³C NMR spectrum of compound **2e**




Fig. S44. Low-field part of the ¹³C NMR spectrum of compound **2e**




Fig. S45 Relative IC₅₀ values characterizing inhibitory activities of **1i-K** (1) and **1h-K** (2) with respect to protein tyrosine phosphatases PTP1B (green), TC-PTP (yellow), PTPβ (red) и LAR-PTP (blue)

The activities of **1i-K** and **1h-K** were determined in 0.05 M Bis-Tris buffer, pH 7.2 (PTP1B, TC-PTP, LAR-PTP) and pH 7.0 (PTPβ). *p*-Nitrophenylphosphate was used as a substrate (2 mM for PTP1B, TC-PTP, LAR-PTP and 1 mM for PTPβ)